F. Mennini, L. Gitto, R. Scrivo, F. Drago, Marco Iezzi, L. Terranova, M. Ruggeri, A. Marcellusi, S. Russo, R. Viti, A. Cicchetti
{"title":"The Promotion of Drug Innovation in Italy: Critical Aspects and Unsolved Problems","authors":"F. Mennini, L. Gitto, R. Scrivo, F. Drago, Marco Iezzi, L. Terranova, M. Ruggeri, A. Marcellusi, S. Russo, R. Viti, A. Cicchetti","doi":"10.5301/GRHTA.5000216","DOIUrl":null,"url":null,"abstract":"The pharmaceutical sector is characterized by the level of investments required in response to the growing challenges in terms of demand for health.In most European countries the pharmaceutical industry, through production, research, intermediate goods and wages, contributes to GDP for a value of about 1%. The impact of the pharmaceutical industry on the added value varies from 23 billion euro in Switzerland to 9.6 billion euro in Spain; for Italy, this value is about 14 billion euro, higher than the average of other European countries.However, despite these positive findings, Italy can hardly keep up with other European countries in investments in R&D in the pharmaceutical sector.An even larger amount of resources is required by the development of personalized therapies and new generation drugs, e.g. developed through biotechnology, which are more effective in responding to complex health needs. Clear rules, aimed at defining and fostering innovation, together with competitive pricing models, are require...","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"29 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global and Regional Health Technology Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5301/GRHTA.5000216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
The pharmaceutical sector is characterized by the level of investments required in response to the growing challenges in terms of demand for health.In most European countries the pharmaceutical industry, through production, research, intermediate goods and wages, contributes to GDP for a value of about 1%. The impact of the pharmaceutical industry on the added value varies from 23 billion euro in Switzerland to 9.6 billion euro in Spain; for Italy, this value is about 14 billion euro, higher than the average of other European countries.However, despite these positive findings, Italy can hardly keep up with other European countries in investments in R&D in the pharmaceutical sector.An even larger amount of resources is required by the development of personalized therapies and new generation drugs, e.g. developed through biotechnology, which are more effective in responding to complex health needs. Clear rules, aimed at defining and fostering innovation, together with competitive pricing models, are require...